Durata Therapeutics, Inc.

Michael W. Dunne is a physician trained in infectious diseases. He is presently the Chief Medical Officer for Durata Therapeutics, Inc, a biotechnology company developing antibiotics for drug resistant infections. Previously he has served as a Vice President of Clinical Development at Pfizer, helping to guide strategic investments in the anti-infective portfolio of compounds while providing direct oversight to the clinical trial programs leading to registration. He has played a leadership role in the development of antibacterial, anti-fungal and antiviral compounds, including drugs used for the treatment of respiratory tract infection, HIV infection and malaria. He also contributed to the policy group at Pfizer, serving as a Vice President of Portfolio Policy. He completed his medical school training at the State University of New York Health Sciences Center in Brooklyn and Internal Medicine residency at Hartford Hospital and Yale University School of Medicine, continuing at Yale for his fellowship training in infectious diseases and pulmonary medicine. He is a member of the infectious Diseases Society of America, the American Society of Microbiology as well as the American College of Physicians.